John Russell

John Russell is a well-respected leader in the medical device and diagnostic sectors of healthcare with over 30 years of experience. Prior to joining Ultromics, Russell served as the CEO and Board Member of Cardiva Medical, Inc. where he expanded the company's commercialization of its vascular closure devices and developed the first multi-vessel closure system for cardiac ablation procedures. Russell also served as CEO of Corventis, Inc., which pioneered the industry's first wearable and wireless cardiac monitoring patch. Earlier in his career, Russell played a key role in the development and commercial introduction of heart failure therapies and monitoring systems at Guidant and Boston Scientific.

Effective from 1st March, Russell succeeds Dr. Helen Routh who, for the past five years, has played a key role in the early growth of Ultromics from inception to Series B. Dr. Routh will continue to serve as a Non-Executive Director on the Board, providing valuable expertise to the company.

In his new role as Executive Chairman, John Russell will support the company's commercial scaling efforts and work closely with the Ultromics team to deliver on its mission of improving patient lives through earlier and more precise diagnosis of heart failure, a life-limiting condition that affects more than 64 million people worldwide. Russell's extensive experience in sales, marketing, business development, and research and development will be invaluable in driving the growth and success of Ultromics.